Pacific Biosciences
PACB
229 hedge funds and large institutions have $332M invested in Pacific Biosciences in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 82 increasing their positions, 60 reducing their positions, and 71 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 60
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10.34% less ownership
Funds ownership: 99.33% → 88.98% (-10%)
15% less funds holding
Funds holding: 268 → 229 (-39)
21% less call options, than puts
Call options by funds: $2.38M | Put options by funds: $3M
51% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 71
67% less capital invested
Capital invested by funds: $1.01B → $332M (-$674M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$12.6M |
| 2 |
MA
Madrone Advisors
Menlo Park,
California
|
+$11.7M |
| 3 |
Millennium Management
New York
|
+$4.47M |
| 4 |
Goldman Sachs
New York
|
+$3.59M |
| 5 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$3.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$31.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$26.3M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$24.9M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$17.2M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$11.7M |
PACB Hedge Fund Activity: Q2 2024 in Review
229 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2024, worth a combined $332M — down 67% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of PACB and 35 opened new positions — a net loss of 36 holders — while 60 trimmed existing stakes and 82 added.
The largest buyer was Edmond de Rothschild Holding, adding an estimated $12.6M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $31.5M sold.
- 229 institutional investors held Pacific Biosciences (PACB) as of Q2 2024, down from 268 in Q1 2024.
- Funds reported $332M of Pacific Biosciences stock for Q2 2024, down 67% quarter-over-quarter.
- 35 funds opened new Pacific Biosciences positions in Q2 2024 and 71 closed out, a net change of -36 holders.
- The largest Pacific Biosciences buyer in Q2 2024 was Edmond de Rothschild Holding, an estimated $12.6M added.
- The largest Pacific Biosciences seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $31.5M sold.
Based on aggregated 13F filings for Q2 2024.